6Razakjr OA, Tan HC, Yip WL, et al. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention. J Interv Cardiol, 2005,18:33-37.
7Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction ( TIMI), Phase Ⅱ Trial. Ann Intern Med, 1991,115:256-265.
8Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol, 2004,44:14-19.
9Wyss CA, Roffi M. Platelet inhibition in percutaneous coronary interventions. Herz. ,2005,30 : 189-196.
10Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J, 2005,26 : 804-847.
3Montalescot G,Barragan P,Wittenbery O,et al.For the ADMIRAL investigators.Platelet glycopretion Ⅱb/Ⅲa inhibition with coronary stenting for acute myocardial infarction.N Eng J Med,2001,21:1895-1903.
4Lee DP,Herity NA,Hiatt BL,et al.Adjunctive platelet glycoprotein Ⅱb/Ⅲa inhibition with tirofiban before primary angioplasty improves angiographic outcome:Results of the Tirofiban give in the Emergency Room before primary angioplasty (TIGER-PA) pilot trial.Circulation,2003,107:1497-1501.
5The TIMI study group.The thrombolysis in myocardial infarction (TIMI) trial;phase I findings.N Engl J Med,1985,312:932-936.
6Kimmelstiel C,Badar J,Covic L,et al.Pharmacodynamics and pharmacokinetics of the platelet GPⅡb/Ⅲa inhibitor tirofiban in patients undergoing percutaneous coronary intervention:implications for adjustment of tirofiban and clopidogrel dosage.Thromb Res,2005,116:55-66.
7Ernst NM,Suryapranata H,Miedema K,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coll Cardiol,2004,44:1187-1193.
8Morrow DA,Sabatine MS,Antman EM,et al.Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).Am J Cardiol,2004,94:774-776.
9Valgimigli M,Percoco G,Barbieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty:the ADVANCE Trial.J Am Coll Cardiol,2004,44:14-19.
10Wyss CA,Roffi M.Platelet Inhibition in Percutaneous Coronary Interventions.Herz,2005,30:189-196.
